Market revenue in 2023 | USD 674.1 million |
Market revenue in 2030 | USD 1,438.8 million |
Growth rate | 11.4% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.07% in 2023. Horizon Databook has segmented the Europe head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Europe accounts for a considerable revenue share of the head and neck cancer therapeutics market due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced healthcare infrastructure, which is anticipated to boost clinical research prospects in the region significantly.
Moreover, market growth can be attributed to the substantial prevalence of head and neck cancer in the region. According to a research article published in the Oral Oncology journal in October 2022, it is estimated that the prevalence of head and neck cancer in Europe is around 21.8 per 100,000, while the mortality is around 15.6 per 100,000 population.
According to IARC, the number of new lip and oral cavity cancer cases is estimated to increase from 65,279 in 2020 to 71,257 by 2030. Furthermore, the awareness programs conducted by respective governments also support the growth of this market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe head and neck cancer therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account